Cancer Control最新文献

{"title":"Factors Contributing to Late Breast Cancer Diagnosis at the Brazzaville University Hospital in 2020, Congo: A Cross-Sectional Analytic Study.","authors":"Michel Ilboudo, Sylvain Honoré Woromogo, Dagnagnéwendé Dieudonné Kaboré, Nina Assanatou Jumelle Zerbo, Jean Bernard Nkoua Mbon","doi":"10.1177/10732748241270634","DOIUrl":"10.1177/10732748241270634","url":null,"abstract":"<p><strong>Objectives: </strong>Breast cancer is leading the cancer incidence and mortality ranks worldwide. Currently, breast cancer represents 30.1% of all cancers occurring in women in Congo. In sub-Saharan Africa, breast cancer is diagnosed delayed in 70% of cases. The purpose of this work is to study the epidemiological aspects of patients with late diagnosis of breast cancer at the Brazzaville University Hospital, Congo.</p><p><strong>Methods: </strong>We carried out a cross-sectional analytic study in the medical oncology service of the University Hospital of Brazzaville. We used systematic, exhaustive sampling. Logistic regression was used for data analysis, and <i>P</i> values ≤5% were considered significant.</p><p><strong>Results: </strong>Data for 182 patients were collected. Delay in diagnosis represented 91.21% of cases. Delay in diagnosis was significantly associated with lack of finance (<i>P</i> = 0.011) and with breast cancer stages greater than 2 (<i>P</i> < 0.001), but the proximity to the center was suggestive. Multivariate analysis revealed an association between diagnostic delay and proximity to the center (<i>P</i> = 0.025) as well as with breast cancer stages greater than 2 (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>The delay in breast cancer diagnosis widely discussed in the literature remains relevant in Congo. Routine screening, the construction of a cancer center and its optimal equipment, and the subsidy of care are all critical factors for battling delayed breast cancer diagnosis in Congo.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241270634"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment.","authors":"Bi Sheng, Dong Wang, Jingjing Wang","doi":"10.1177/10732748241309046","DOIUrl":"10.1177/10732748241309046","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate hepatitis B virus (HBV) reactivation and its effect on tumor response and survival outcomes in patients with HBV-related advanced hepatocellular carcinoma (HCC) undergoing lenvatinib plus camrelizumab treatment.</p><p><strong>Methods: </strong>216 patients with HBV-related advanced HCC receiving lenvatinib and camrelizumab were enrolled. Overall survival (OS), progression-free survival, and tumor response were evaluated. Univariate and multivariate analyses were performed to determine risk factors for HBV reactivation.</p><p><strong>Results: </strong>HBV reactivation occurred in 24 patients (11.1%). It was associated with poor survival and tumor response in these patients. Undetectable DNA levels, the absence of antiviral therapy, and high ALT levels were identified as vital risk factors for HBV reactivation. After receiving or adjusting the antiviral strategy, tumor response improved in patients with HBV reactivation.</p><p><strong>Conclusions: </strong>HBV reactivation could occur in patients with HBV-related HCC, treated with lenvatinib and camrelizumab, worsening tumor response and patient survival. Regular monitoring of the indicators of HBV infection and effective antiviral treatments are recommended for these patients to prevent severe complications.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241309046"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence OF HPV IN a Peruvian Healthcare Network: A Descriptive Cross-Sectional Study.","authors":"Jhajaira M Araujo, Maria Ramon-Cotrina, Rosa Quispe-Martinez, Mayra Rios-Rios, Maribel Quispe-Gonzaga, Carlos O Saldaña-Reyes, Paula Medina, Melanie Cornejo, Joseph A Pinto, Richard Dyer","doi":"10.1177/10732748251318386","DOIUrl":"10.1177/10732748251318386","url":null,"abstract":"<p><strong>Introduction: </strong>Human papillomavirus (HPV) infection is a common sexually transmitted infection often associated with cancer development. This study aimed to estimate the prevalence of HPV in women receiving care at the AUNA healthcare network in Peru.</p><p><strong>Methods: </strong>We conducted an observational, descriptive, cross-sectional, retrospective study. A de-identified database of HPV-positive women who underwent the BD Onclarity™ HPV Assay between December 2018 and December 2021 at Auna clinics was analyzed. The database contained information regarding age, city, and HPV type. High-risk HPV types were analyzed individually (16, 18, 31, 45, 51, 52) and pooled [P1 (33, 58), P2 (56,59,66), and P3 (35,39,68)]. The study was approved by an independent research ethics committee in Peru.</p><p><strong>Results: </strong>Of 68,714 women included in the study, the HPV prevalence was 14.21% (N = 9765, 95%CI:13.95%-14.47%). The highest prevalence was detected in Piura (16.85%, 95%CI:15.40%-18.38%), where HPV-51, HPV-52, HPV-P1, HPV-P2, and HPV-P3 were most common compared to other Peruvian cities included in the study. In Arequipa, the prevalence was the lowest (13.58%, 95%CI:12.38%-14.85%), but the percentage prevalence of HPV-16 was the highest compared to other cities. The prevalence of multiple HPV infections was 2.88% (N = 1981, 95%CI:2.76%-3.01%), with most of them co-presenting two types of HPV (N = 1522). The most frequent co-occurrences were P2 and P3, P2 and 52, and P2 and 16. Among HPV-positive women, the mean age was 41.31 years (±9.48) and 25.29% were in the 31-35 years group. HPV-P2 was the most frequent in all age groups except in the 65-72 years group, where HPV-P3 was the most common.</p><p><strong>Conclusion: </strong>HPV prevalence was shown to be highest in Piura, with the most prevalent types being HPV-16, HPV-52, and HPV-P2 (HPV-56, -59, -66). HPV infection was found to be more frequent among women in the 31-35 years age group.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318386"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking LEDGF/p75 Overexpression With Microsatellite Instability and KRAS Mutations: A Small-Scale Study in Colorectal Cancer.","authors":"Victoria Liedtke, Thomas Wartmann, Wenjie Shi, Ulf D Kahlert","doi":"10.1177/10732748251313499","DOIUrl":"10.1177/10732748251313499","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer (CRC) ranks third in men and second in women, with 153,020 new cases and 52,550 deaths in 2023, and with a projected incidence of 2.2 million new cases by 2030 due to lifestyle changes and enhanced diagnostic capabilities. Identification and analysis of new biomarkers, like lens epithelium-derived growth factor splice variant of 75 kDa (LEDGF/p75), which is known to play a crucial role as stress-related oncogene, can make a significant contribution in facilitating early CRC detection.</p><p><strong>Methods: </strong>This study analyzed the expression of LEDGF/p75 and the ubiquitin E2 conjugating enzyme UBC13 in 15 CRC tissue samples and adjacent non-tumor tissues. All patient samples underwent NGS-based mutation analysis beforehand. The western blot technique was used for protein analysis, and the results were further validated using mRNA expression data from 521 patient samples from the TCGA database.</p><p><strong>Results: </strong>LEDGF/p75 expression was significantly elevated in nearly all tumor tissue samples compared to adjacent tissue (11/15, 73.3%). Additionally, the UBC13 enzyme, a key regulator in the degradation of signaling molecules, was also increased in most tumor tissue samples (9/15, 60.0%). Co-overexpression of LEDGF/p75 and UBC13 was evident in 6/6 patients. Patients with KRAS and MSH2 mutations showed a 75% and 100% correlation with LEDGF/p75 overexpression, respectively.</p><p><strong>Conclusion: </strong>This study confirms the upregulation of LEDGF/p75 in CRC and shows its correlation with KRAS and MSH2 mutations. The interaction of LEDGF/p75 with DNA damage response proteins may contribute to drug resistance and increased tumor aggressiveness. LEDGF/p75's potential as a prognostic biomarker independent of lymph node involvement or CEA levels highlights its potential in personalized therapy, and warrants further research into its therapeutic targeting.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251313499"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study.","authors":"Yi Peng, De Wu, Jing Tang, Xiaobing Li","doi":"10.1177/10732748251318383","DOIUrl":"10.1177/10732748251318383","url":null,"abstract":"<p><strong>Objective: </strong>To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC).</p><p><strong>Materials and methods: </strong>We analyzed data from ES-SCLC patients who achieved stable disease (SD) following initial chemotherapy combined with immunotherapy. These patients subsequently received maintenance therapy (MT) with a combination of anlotinib and PD-1/L1 inhibitors. The primary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs).</p><p><strong>Results: </strong>Preliminary findings suggest that this regimen is highly effective, with a median PFS of 6 months and OS of 13.5 months, alongside a DCR exceeding 60%. Subgroup analysis revealed enhanced efficacy in patients with fewer than three metastatic sites and those who experienced hypertension, proteinuria, or hand-foot syndrome during MT. Mechanistic studies showed a notable increase in the proportion of CD8+ T cells in the peripheral blood post-MT, correlating with improved outcomes. These findings imply that the therapeutic effect of MT may be partly due to the direct activation of CD8+ T cells, producing a synergistic anti-tumor response. Despite the prevalence of AEs, AEs were generally manageable, underscoring anlotinib's potential in this context.</p><p><strong>Conclusion: </strong>The combination of anlotinib and PD-1/L1 inhibitors offers promising efficacy and manageable AEs in MT, making it a viable option for ES-SCLC patients who achieve SD post-initial therapy. These results justify further prospective studies to validate this approach.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318383"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shooting for the Moon: Can We Cut Cancer Mortality in Canada By 50% By 2050?","authors":"Keaton Banik, Yibing Ruan, Mariet M Stephen, John M Hutchinson, Chantelle Carbonell, Matthew T Warkentin, Andrew Coldman, Rochelle Garner, Hawre Jalal, Darren R Brenner","doi":"10.1177/10732748251319485","DOIUrl":"10.1177/10732748251319485","url":null,"abstract":"<p><strong>Introduction: </strong>The United States of America reignited their Cancer Moonshot Initiative in 2022 with an ambitious goal to reduce cancer mortality by 50% over the next 25 years. In this study, we estimated how and whether a similar cancer control initiative could be achieved in Canada.</p><p><strong>Methods: </strong>We used the OncoSim microsimulation suite to address three questions: (1) what is the expected mortality from cancer in Canada by 2050 given the current trends?; (2) what would be the maximal impact on reducing cancer mortality with prevention and increased screening activities? and, (3) if a 50% reduction in projected cancer mortality could not be achieved through the primary and secondary intervention efforts, what additional advancements and discoveries would be needed to fill the \"lunar gap\"? We modeled the joint impact of risk-factor reduction and screening, as well as the independent effects of prevention and screening alone, on projected cancer mortality.</p><p><strong>Results: </strong>Our models suggest that there will be an expected 133,395 cancer deaths in 2050 in Canada. Approximately 33% of these cancer deaths could be prevented by risk-factor reduction and increased screening programs by the year 2050. This would leave a \"lunar gap\" of about 16%-17% that would need to be bridged with novel discoveries in cancer risk prevention, early detection, and treatment.</p><p><strong>Conclusion: </strong>While current knowledge and implementation of prevention and screening would have a considerable impact on a Canadian cancer moonshot, additional efforts are needed to implement cancer control initiatives and fuel additional discoveries to fill the gap.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251319485"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases.","authors":"Neyran Kertmen, Gozde Kavgaci, Serkan Akin, Gokcen Coban, Ahmet Ilkay Isikay, Gozde Yazici","doi":"10.1177/10732748251322072","DOIUrl":"10.1177/10732748251322072","url":null,"abstract":"<p><strong>Introduction: </strong>Recent advancements in immunotherapy have offered new possibilities for treating aggressive glioblastoma (GBM) and brain metastases. However, evaluating treatment responses remains complex, prompting the development of the immunotherapy-specific Response Assessment in Neuro-Oncology (iRANO) criteria. Herein, we present case reports illustrating the intricacies of interpreting imaging changes post-immunotherapy, emphasizing the need for a comprehensive approach to assessing treatment effectiveness.</p><p><strong>Case reports: </strong>Case 1 discusses a 41-year-old male with GBM, highlighting the challenges of differentiating tumor progression from treatment-induced pseudoprogression. Case 2 discusses a 45-year-old female with brain metastatic malignant melanoma, presenting radiological evidence of progressive disease while undergoing nivolumab treatment. Case 3 discusses a 37-year-old male with GBM, where radiological evidence indicates progressive disease while receiving pembrolizumab treatment.</p><p><strong>Management and outcomes: </strong>In case 1, we discussed the challenges of distinguishing true tumor progression from treatment-induced pseudoprogression, leading to the continuation of the same treatment due to pseudoprogression. In case 2, post-surgery pathology revealed radionecrosis and treatment-related changes, guiding the continuation of nivolumab therapy. Case 3 involved a pathologically confirmed progression, and the patient received best supportive care due to his performance status.</p><p><strong>Discussion: </strong>Despite aggressive treatment regimens, the prognosis for GBM patients remains poor, underscoring the necessity for innovative therapeutic strategies. Immunotherapy holds promise in reshaping the treatment landscape for GBM and brain metastases, but further research and refinement of assessment criteria are crucial. Throughout our cases, we discuss the iRANO criteria, developed to overcome the limitations of the RANO criteria in capturing immunotherapy responses, particularly pseudoprogression.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251322072"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing Artificial Intelligence-Powered Virtual Tumor Board Meetings in Pakistan.","authors":"Saqib Raza Khan, Anoud Khan, Aryan Tareen","doi":"10.1177/10732748251331753","DOIUrl":"10.1177/10732748251331753","url":null,"abstract":"<p><p>Equitable cancer care in low- and middle-income countries is crucial as mortality rates continue to rise. Artificial intelligence (AI)-powered Virtual Tumor Board Meetings (VTBMs) offer an innovative solution that facilitates real-time collaboration between experts to improve patient outcomes. By integrating AI-powered tools, VTBMs can improve diagnostic accuracy and personalize treatment plans using various data sources such as medical images and genomic profiles. In Pakistan, with limited healthcare resources and a high economic burden, the introduction of AI-powered VTBMs has the potential to revolutionize cancer care. This strategic approach will not only address the current challenges in Pakistan, but also serve as a model for improving cancer care in various developing countries.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251331753"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cultural and Linguistic Adaptation of an Evidence-Based Tailored Navigation Intervention to Increase Cancer Screening Uptake Among Southeast Asian Women.","authors":"Jennifer Kue, Judith A Tate, Bárbara Piñeiro, Laura A Szalacha, Bounthanh Phommasathit, Somany Pich, Usha Menon","doi":"10.1177/10732748251329867","DOIUrl":"10.1177/10732748251329867","url":null,"abstract":"<p><p>BackgroundSoutheast Asian immigrant women in the U.S. have high rates of breast and cervical cancer, yet they are the least likely of all racial/ethnic groups to get screened. To address this disparity, we adapted the evidence-based Tailored Intervention Messaging System^© (TIMS^©), which uses tailored messages and navigation by culturally and linguistically matched community health advisors to overcome barriers to cancer screening.ObjectivesThis study describes the cultural and linguistic adaptation of TIMS^© to improve breast and cervical cancer screening among Southeast Asian immigrant women in the U.S.MethodsGuided by Stirman et al.'s adaptation framework, we conducted focus groups and in-depth interviews to identify key constructs related to cancer screening (knowledge, perceived barriers, perceived risk, benefits, self-efficacy). Using the TIMS^© and the thematic content from qualitative data, we modified messages for content and context. Messages were divided into three categories: 1) existing messages identified in thematic analyses, 2) existing messages not identified in thematic analyses, and 3) new messages that emerged from thematic analyses.ResultsContextual and content modifications were made to the TIMS^© message library. Messages were translated into Lao, Khmer, and Vietnamese. Through an iterative process, the investigator, community health advisors, and cultural community advisory board members reviewed and revised the messages for translation accuracy, relevance, and clarity.ConclusionUsing relatable language and context is critical to engaging women from Southeast Asian communities in improving breast and cervical cancer screening uptake. This adaptation approach can be applied to tailor interventions for other languages, cultures, and underrepresented groups.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251329867"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.","authors":"Donghong Wang, Zhibin Ma","doi":"10.1177/10732748251330713","DOIUrl":"10.1177/10732748251330713","url":null,"abstract":"<p><p>BackgroundPancreatic cancer places a substantial global health and economic burden. However, the epidemiological characteristics and chronological trends of pancreatic cancer in high-income Asia-Pacific have not been systematically analyzed.MethodsData obtained from the GBD 2021 database were used for this cross-country secondary analysis. We used Joinpoint regression to analyze the temporal trends of pancreatic cancer disease burden in the high-income Asia-Pacific. Age-period-cohort model was used to estimate and describe the impact of age, period, and cohort effects on health outcomes. Bayesian age-period-cohort model was used for the projection of pancreatic cancer incidence from 2022 to 2036.ResultsIn high-income Asia-Pacific, the age-standardized prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life-years (DALYs) rate (ASDR) were estimated to be 11.2 (95% UI, 9.69-12.17), 9.56 (95% UI, 8.34-10.34), and 197.6 (95% UI, 178.87-210.6) per 100 000 population, respectively, in 2021, which were all higher than those in across Asia. From 1990 to 2002, the age-standardized incidence rates (ASIRs) trend was rather stable. Instead, the ASIRs trend went up gradually from 2002 to 2011 in both males (APC = + 1.03, 95% CI: 0.85, 1.20) and females (APC = + 1.64, 95% CI: 1.40, 1.89). ASIRs and ASMRs went up considerably with increasing age, especially over 60. The ASIRs in the high-income Asia-Pacific region are predicted to go down in the years ahead, from approximately 12.81 in 2021 to approximately 11.11 in 2036 for males, and from approximately 8.97 in 2021 to approximately 8.42 in 2036 for females.ConclusionA comprehensive upward trend in ASIRs, ASPRs, ASMRs, and ASDRs of pancreatic cancer was observed in the high-income Asia-Pacific between 1990 and 2021. Given the poor prognosis of pancreatic cancer, prevention strategies are paramount, especially for modifiable factors like smoking, alcohol drinking, and obesity.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330713"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}